A preclinical trial of the reassortant influenza virus vaccinе strain A/17/Quail/Hong Kong/97/84 (H9N2)

Abstract

In this work, we examined the reassortant influenza virus strain A/17/Quail/Hong Kong/97/84 (H9N2) prepared at the Virology Department, Institute of Experimental Medicine, Russian Academy of Medical Sciences. The A/Leningrad/134/17 (H2N2)-based vaccine candidate contained hemagglutinin and the neuraminidase from the nonpathogenic avian influenza A virus A(H9N2) of the G1 antigenic lineage. The vaccine candidate showed the ts-properties and cold adaptation. When administered intranasally to mice, the vaccine strain A(H9N2) was attenuated. It did not multiply in the lungs but was reproduced well in the nasal cavity, causing the production of the post-vaccination antibody. The A/17/Quail/Hong Kong/97/84(H9N2) virus was immunogenic when administered to mice as a LAI V intranasally or as a IIV intramuscularly. Intranasal A(H9N2) LAIV stimulated ocal production of the antibodies, which resulted in reduction in lung titers of the challenge virus G9.

Keywords

• avian influenza virus
• influenza vaccine